Clinical Trial Update: Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating molecular residual disease-guided adjuvant therapy in renal cell carcinoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Renal Cell Carcinoma | Phase 2 | Status: RECRUITING